Daiwa Securities Group Inc. Grows Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Daiwa Securities Group Inc. raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 17.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,302 shares of the medical research company’s stock after buying an additional 6,651 shares during the quarter. Daiwa Securities Group Inc.’s holdings in IQVIA were worth $8,706,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Capital Performance Advisors LLP purchased a new stake in IQVIA in the third quarter valued at approximately $27,000. Avior Wealth Management LLC increased its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the last quarter. Synergy Asset Management LLC purchased a new position in shares of IQVIA in the 4th quarter worth $33,000. Assetmark Inc. grew its position in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in IQVIA during the third quarter worth about $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of research reports. Stephens started coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. Stifel Nicolaus decreased their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Finally, JPMorgan Chase & Co. reduced their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Price Performance

IQV opened at $183.72 on Wednesday. The company has a market capitalization of $32.39 billion, a P/E ratio of 24.50, a PEG ratio of 1.99 and a beta of 1.50. The company has a 50-day moving average of $197.36 and a 200-day moving average of $211.78. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $261.72.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.